Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis LMICs Strategic Innovative Therapies (people) by Year
Novartis LMICs Strategic Innovative Therapies (people): 2,161,186 in FY2025, up 19.6% from a year earlier.
Latest, FY2025
2,161,186
Period ended Dec 31, 2025
Change on a year earlier
+19.6%
1,806,386 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below
Where the FY2025 figure comes from
“| Patients reached with strategic innovative therapies in LMICs | 2 161 186 | 1 806 386 | | 31 | ”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025 & Public Commitments.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | LMICs Strategic Innovative Therapies (people) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,161,186 | +19.6% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 1,806,386 | +15.2% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 1,568,574 | +31.0% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2022 | Dec 31, 2022 | 1,197,352 | +26.3% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2021 | Dec 31, 2021 | 947,699 | +36.2% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2020 | Dec 31, 2020 | 695,669 | +27.0% | Novartis Form 6-K (0001370368-23-000009) ↗ |
| FY2019 | Dec 31, 2019 | 547,664 | – | Novartis Official IR / Sustainability Report — novartis-update-public-commitments-2025.pdf ↗ |
Cite this data
StockData. (2026). Novartis LMICs Strategic Innovative Therapies (people), annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/access-patients-strategic-lmic
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.